XtalPi announced that Viva-Thera nominated a preclinical candidate targeting the membrane-proximal external region of HIV-1 gp41. The partners completed discovery and optimization in seven months using structural research and an AI platform.
Source: Vietnam Investment Review
Source: Vietnam Investment Review
XtalPi AI platform accelerates HIV-1 drug candidate selection within seven months
Technology firm XtalPi utilised artificial intelligence models to nominate a preclinical candidate targeting the MPER region of HIV-1 gp41 for portfolio company Viva-Thera within seven months.
vir.com.vn
September 23, 2026 at 9:50 AM
XtalPi announced that Viva-Thera nominated a preclinical candidate targeting the membrane-proximal external region of HIV-1 gp41. The partners completed discovery and optimization in seven months using structural research and an AI platform.
Source: Vietnam Investment Review
Source: Vietnam Investment Review
XtalPi's New Gut-Restricted Drug KQTD-126 Aims to Transform Chronic Pain Treatment#USA#Boston#XtalPi#IBS#KQTD-126
XtalPi's New Gut-Restricted Drug KQTD-126 Aims to Transform Chronic Pain Treatment
XtalPi has submitted an IND application for KQTD-126, a groundbreaking gut-restricted pan-TRK inhibitor for chronic intestinal pain, marking a significant advance in treatment options for IBS and IBD.
third-news.com
September 25, 2026 at 12:39 AM
How XtalPi's AI is Accelerating HIV Research and Drug Development for Viva-Thera#China#Shenzhen#XtalPi#HIV_Research#Viva-Thera
How XtalPi's AI is Accelerating HIV Research and Drug Development for Viva-Thera
XtalPi partners with Viva-Thera to advance HIV drug development using AI, achieving a preclinical milestone in just seven months.
third-news.com
September 22, 2026 at 5:44 PM
How XtalPi's AI is Accelerating HIV Research and Drug Development for Viva-Thera#China#Shenzhen#XtalPi#HIV_Research#Viva-Thera
The structure constrained the design. Experiments constrained the models.
7 months later, what left that loop is a preclinical candidate against #HIV entry at MPER, ready for the next studies.
The rest — potency in the right models, a path through development — is still ahead.
Read more:
7 months later, what left that loop is a preclinical candidate against #HIV entry at MPER, ready for the next studies.
The rest — potency in the right models, a path through development — is still ahead.
Read more:
XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program
/PRNewswire/ -- XtalPi (HKEX: 2228) announced that Viva-Thera, a biotechnology company it incubated and backs as a strategic shareholder, has nominated a...
www.prnewswire.com
September 23, 2026 at 9:35 AM
The structure constrained the design. Experiments constrained the models.
7 months later, what left that loop is a preclinical candidate against #HIV entry at MPER, ready for the next studies.
The rest — potency in the right models, a path through development — is still ahead.
Read more:
7 months later, what left that loop is a preclinical candidate against #HIV entry at MPER, ready for the next studies.
The rest — potency in the right models, a path through development — is still ahead.
Read more:
Xstal Pi, also in China www.forbes.com/sites/zinnia... (🧵 6/14) 🇨🇳
Sequoia China-Backed AI Startup Xtalpi To Partner With Pharma Giant Eli Lilly In $250 Million Novel Drug Deal
Xtalpi said the drug candidates will target a disease that currently has no medicine available.
www.forbes.com
January 5, 2025 at 3:22 PM
Xstal Pi, also in China www.forbes.com/sites/zinnia... (🧵 6/14) 🇨🇳
🔴 XtalPi sent the FDA an IND for KQTD-126, a gut-restricted pan-TRK inhibitor for IBS/IBD pain. Preclinical data claim sub-nanomolar potency and a gut-to-blood ratio above 1,000:1. That’s a filing, not a drug; avoiding neurological toxicity is the entire bet. Human gut…
September 25, 2026 at 1:32 PM
🔴 XtalPi sent the FDA an IND for KQTD-126, a gut-restricted pan-TRK inhibitor for IBS/IBD pain. Preclinical data claim sub-nanomolar potency and a gut-to-blood ratio above 1,000:1. That’s a filing, not a drug; avoiding neurological toxicity is the entire bet. Human gut…
XtalPi Partners with Biopharma to Develop Innovative Small Molecule Therapies Targeting GPCRs#USA#Boston#Biopharma#XtalPi#GPCR
XtalPi Partners with Biopharma to Develop Innovative Small Molecule Therapies Targeting GPCRs
XtalPi has announced a strategic partnership with a major biopharma company to develop small molecule therapeutics targeting GPCRs using AI and robotics in drug discovery.
third-news.com
June 10, 2026 at 1:26 PM
XtalPi Partners with Biopharma to Develop Innovative Small Molecule Therapies Targeting GPCRs#USA#Boston#Biopharma#XtalPi#GPCR
Empresa chinesa de medicamentos com IA projeta lucro após salto de 193% na receita
Receita da XtalPi cresceu para 780 milhões de yuans; empresa estima lucro líquido de 100 milhões em 2025.
Mais detalhes: s.rtbrasil.com/ncs
Receita da XtalPi cresceu para 780 milhões de yuans; empresa estima lucro líquido de 100 milhões em 2025.
Mais detalhes: s.rtbrasil.com/ncs
Empresa chinesa de medicamentos com IA projeta lucro após salto de 193% na receita
Receita da XtalPi cresceu para 780 milhões de yuans; empresa estima lucro líquido de 100 milhões em 2025.
s.rtbrasil.com
March 5, 2026 at 6:10 AM
Empresa chinesa de medicamentos com IA projeta lucro após salto de 193% na receita
Receita da XtalPi cresceu para 780 milhões de yuans; empresa estima lucro líquido de 100 milhões em 2025.
Mais detalhes: s.rtbrasil.com/ncs
Receita da XtalPi cresceu para 780 milhões de yuans; empresa estima lucro líquido de 100 milhões em 2025.
Mais detalhes: s.rtbrasil.com/ncs
JinkoSolar pushes on perovskite-silicon tandem solar with new partnership www.pv-magazine.com/2026/01/08/j...
JinkoSolar pushes on perovskite-silicon tandem solar with new partnership
JinkoSolar has signed a strategic cooperation agreement with XtalPi, an “AI for Science” platform company, to pursue high-throughput R&D on perovskite-crystalline-silicon tandem solar cells using an A...
www.pv-magazine.com
January 12, 2026 at 7:50 PM
JinkoSolar pushes on perovskite-silicon tandem solar with new partnership www.pv-magazine.com/2026/01/08/j...
XtalPi's Automation Solutions Make Major Impact at BASF's Innovation Campus#Shanghai#USA#Automation#XtalPi#BASF
XtalPi's Automation Solutions Make Major Impact at BASF's Innovation Campus
XtalPi has successfully implemented an advanced automated workstation at BASF, revolutionizing the way stability testing is conducted in the chemical industry.
third-news.com
February 9, 2026 at 12:25 PM
XtalPi's Automation Solutions Make Major Impact at BASF's Innovation Campus#Shanghai#USA#Automation#XtalPi#BASF
‘automated experimental setup w/ >200 robots & an end-to-end workflow that can cover precursor synthesis, device fabrication, in-situ characterization, laser processing, vacuum deposition & ageing tests, feeding results back into models to refine subsequent experiments’ in perovskite-silicon tandems
JinkoSolar pushes on perovskite-silicon tandem solar with new partnership
JinkoSolar has signed a strategic cooperation agreement with XtalPi, an “AI for Science” platform company, to pursue high-throughput R&D on perovskite-crystalline-silicon tandem solar cells using an A...
www.pv-magazine.com
January 12, 2026 at 12:24 AM
‘automated experimental setup w/ >200 robots & an end-to-end workflow that can cover precursor synthesis, device fabrication, in-situ characterization, laser processing, vacuum deposition & ageing tests, feeding results back into models to refine subsequent experiments’ in perovskite-silicon tandems
Ailux Partners with Lilly to Propel Bispecific Antibody Innovations in Drug Development#China#Shanghai#Eli_Lilly#XtalPi#Ailux
Ailux Partners with Lilly to Propel Bispecific Antibody Innovations in Drug Development
Ailux, a subsidiary of XtalPi, is collaborating with Eli Lilly to enhance bispecific antibody development using AI technology for novel therapies.
third-news.com
November 5, 2025 at 12:34 PM
Ailux Partners with Lilly to Propel Bispecific Antibody Innovations in Drug Development#China#Shanghai#Eli_Lilly#XtalPi#Ailux
Pioneering the Future of Drug Discovery: Insights from XtalPi’s International Symposium#China#Shanghai#AI_Drug_Discovery#XtalPi#molecular_glue
Pioneering the Future of Drug Discovery: Insights from XtalPi’s International Symposium
XtalPi recently held its 2026 International Symposium, showcasing innovative AI techniques in molecular glue drug discovery, featuring expert insights worldwide.
third-news.com
January 29, 2026 at 1:29 PM
Pioneering the Future of Drug Discovery: Insights from XtalPi’s International Symposium#China#Shanghai#AI_Drug_Discovery#XtalPi#molecular_glue
XtalPi is scaling up its AI drug pipeline in Shenzhen—integrating omics and clinical data to accelerate novel designs.
AI-driven biotech is on track for a $13B market by 2032.
AI-driven biotech is on track for a $13B market by 2032.
July 1, 2025 at 9:14 PM
XtalPi is scaling up its AI drug pipeline in Shenzhen—integrating omics and clinical data to accelerate novel designs.
AI-driven biotech is on track for a $13B market by 2032.
AI-driven biotech is on track for a $13B market by 2032.
XtalPi's Collaboration with DoveTree: A New Era in Oncology Drug Development#USA#Boston#oncology#XtalPi#DoveTree
XtalPi's Collaboration with DoveTree: A New Era in Oncology Drug Development
XtalPi's strategic partnership with DoveTree progresses in oncology, marking milestones that enhance drug discovery efficiency using AI technology.
third-news.com
May 29, 2026 at 2:26 PM
The Beginning of a New Health Era
Artificial intelligence is already improving and modernizing medicine today. Companies like XtalPi have proven that AI can increase the speed of drug development by up to 90%...
coinmarketcap.com/community/po...
#AI #medicine #healthcare #technology
Artificial intelligence is already improving and modernizing medicine today. Companies like XtalPi have proven that AI can increase the speed of drug development by up to 90%...
coinmarketcap.com/community/po...
#AI #medicine #healthcare #technology
January 26, 2025 at 6:59 AM
The Beginning of a New Health Era
Artificial intelligence is already improving and modernizing medicine today. Companies like XtalPi have proven that AI can increase the speed of drug development by up to 90%...
coinmarketcap.com/community/po...
#AI #medicine #healthcare #technology
Artificial intelligence is already improving and modernizing medicine today. Companies like XtalPi have proven that AI can increase the speed of drug development by up to 90%...
coinmarketcap.com/community/po...
#AI #medicine #healthcare #technology
UCB schakelt Amerikaanse AI in op jacht naar nieuwe medicijnen
UCB schakelt Amerikaanse AI in op jacht naar nieuwe medicijnen
Het Belgische farmabedrijf gaat artificiële intelligentie van het Amerikaanse XtalPi gebruiken om zijn onderzoek naar biologische medicijnen te versnellen. AI bleek al belangrijk voor de ontwikkeling van zijn psoriasmiddel Bimzelx, het nieuwe stermiddel.
www.tijd.be
January 9, 2025 at 7:36 AM
UCB schakelt Amerikaanse AI in op jacht naar nieuwe medicijnen
XtalPi says its AI and robotics platform supported a clinical milestone for ReviR Therapeutics’ investigational therapy RTX-117 targeting a rare neurological disorder.
See how AI and high-throughput automation are shaping R&D: https://ow.ly/UZin50YotCB
#DrugDiscovery #AI #Biotech
See how AI and high-throughput automation are shaping R&D: https://ow.ly/UZin50YotCB
#DrugDiscovery #AI #Biotech
XtalPi’s AI and Robotics Platform Supports Clinical Milestone for ReviR’s RTX-117 -- MedCloudInsider
Drug candidate targeting rare neurological disease advances with support from AI-driven discovery and automation platform.
ow.ly
March 3, 2026 at 3:01 PM
XtalPi says its AI and robotics platform supported a clinical milestone for ReviR Therapeutics’ investigational therapy RTX-117 targeting a rare neurological disorder.
See how AI and high-throughput automation are shaping R&D: https://ow.ly/UZin50YotCB
#DrugDiscovery #AI #Biotech
See how AI and high-throughput automation are shaping R&D: https://ow.ly/UZin50YotCB
#DrugDiscovery #AI #Biotech
In the spotlight today we have XtalPi Inc who will be exhibiting at this year's 9th RSC-CICAG/RSC BMCS-BMCS Artificial Intelligence in Chemistry!
Make sure to visit their stand! 🖼️
📅 Wednesday 2nd - Friday 4th September
📍 Churchill College, Cambridge, UK
To register, please click here 👉 t.ly/AIC26
Make sure to visit their stand! 🖼️
📅 Wednesday 2nd - Friday 4th September
📍 Churchill College, Cambridge, UK
To register, please click here 👉 t.ly/AIC26
August 25, 2026 at 1:28 PM
In the spotlight today we have XtalPi Inc who will be exhibiting at this year's 9th RSC-CICAG/RSC BMCS-BMCS Artificial Intelligence in Chemistry!
Make sure to visit their stand! 🖼️
📅 Wednesday 2nd - Friday 4th September
📍 Churchill College, Cambridge, UK
To register, please click here 👉 t.ly/AIC26
Make sure to visit their stand! 🖼️
📅 Wednesday 2nd - Friday 4th September
📍 Churchill College, Cambridge, UK
To register, please click here 👉 t.ly/AIC26
XtalPi Holdings Reports Interim Results for the First Half of 2026 with Remarkable Growth in AI-Driven Services#China#Shenzhen#Drug_Discovery#XtalPi_Holdings#AI4S
XtalPi Holdings Reports Interim Results for the First Half of 2026 with Remarkable Growth in AI-Driven Services
XtalPi Holdings has unveiled its interim financial results for 2026, showcasing significant revenue growth in AI4S solutions while addressing operational challenges.
third-news.com
August 19, 2026 at 1:49 PM
XtalPi Holdings Reports Interim Results for the First Half of 2026 with Remarkable Growth in AI-Driven Services#China#Shenzhen#Drug_Discovery#XtalPi_Holdings#AI4S
Modern research is adopting innovative solutions such as a Leading AI for Science platform, Advanced Small Molecule Drug Discovery Technology Platform and AI Bispecific Antibody Platform to accelerate the development of next-generation therapies.
Learn more: en.xtalpi.com
Learn more: en.xtalpi.com
XtalPi
en.xtalpi.com
August 8, 2026 at 7:22 AM
Modern research is adopting innovative solutions such as a Leading AI for Science platform, Advanced Small Molecule Drug Discovery Technology Platform and AI Bispecific Antibody Platform to accelerate the development of next-generation therapies.
Learn more: en.xtalpi.com
Learn more: en.xtalpi.com